Navigation Links
The Systemic Lupus Erythematosus Market Will Grow Dramatically Over the Next Decade, Increasing from Approximately $900 Million in 2012 to $4 Billion in 2022
Date:10/30/2013

f Bristol-Myers Squibb's Orencia for the treatment of lupus nephritis, beginning in 2018, will be a significant driver of SLE market growth. Orencia's patient share in 2022 will be modest; however, the anticipated high price of the 30 mg/kg dose being tested in Phase III trials will drive its sales to account for approximately 19 percent of total SLE sales in 2022.

"Benlysta has received a lukewarm reception to the SLE market owing primarily to physician perceptions of its modest efficacy, slow onset to action and inability to be used in the high unmet need population of patients with severe, life-threatening organ involvement," said Decision Resources Analyst Laura Croal, Ph.D. "Owing to its high price in a largely generic market, Benlysta will lead market sales in 2022 on the strengths of its excellent safety profile, demonstrated efficacy in pivotal trials and first-to-market advantage. However, the drug will be vulnerable to emerging agents with acceptable safety profiles that demonstrate improvements in these key perceived weaknesses."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of the
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
2. Rheumatologists in the EU5 Give the Highest Satisfaction and Performance Ratings to Rituxan and Benlysta for the Treatment of Systemic Lupus Erythematosus (SLE)
3. Indias Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. New Findings Offer Systemic Solutions to Address Non-communicable Diseases (NCDs) in Low- and Middle-income Countries
6. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
7. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
8. New ALR-LRI Collaboration to Accelerate New Treatments for Lupus
9. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
10. Lupus Foundation of Florida Applauds Support for Biosimilars Legislation
11. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 31, 2011 Leading events organiser UBM Live ... details of a new Logistics and Supply Chain Zone ... to pharmaceutical contract services and outsourcing. ICSE will take ... Germany and is part of the world,s leading platform ...
... (NASDAQ: UPI ), announced today that the ... (NICE) issued guidance on percutaneous tibial nerve stimulation (PTNS) ... NICE issued similar guidance on PTNS treatment for overactive ... in the UK and Europe to use our Urgent® ...
Cached Medicine Technology:Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 2Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 3United Kingdom's National Institute for Health and Clinical Excellence Issues Guidance on Percutaneous Tibial Nerve Stimulation for Faecal Incontinence 2
(Date:7/10/2014)... 2014 Up to 70% of Parkinson,s disease ... their quality of life. Some patients have disturbed ... staying asleep, while other patients may be subject ... the extreme, PD patients may exhibit REM-sleep behavior ... dream re-enactment, even before motor symptoms appear. A ...
(Date:7/10/2014)... of Huddersfield could help to improve the quality of ... such as butter, mayonnaise, yoghurt and fruit drinks ... for her work. , Katerina gained her MSc degree ... now she has embarked on research for a PhD. ... is investigating the potential of carbohydrates extracted from the ...
(Date:7/10/2014)... 2014) A research review identifying the clinical indicators ... step in the process of developing evidence-based guidelines for ... report published by Neurosurgery , official ... . The journal is published by Lippincott Williams ... Kluwer Health . , Based on analysis of ...
(Date:7/10/2014)... decades, health-conscious people around the globe have taken antioxidant ... was one of the paths to good health and ... of antioxidant supplements have repeatedly dashed the hopes of ... risk. Virtually all such trials have failed to ... in several trials antioxidant supplementation has been linked with ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2
... five-year international clinical study shows that acyclovir, a commonly prescribed ... not affect HIV transmission by people with both viruses. ... Transmission Study, was released by the New England Journal ... will follow in the print edition Feb. 4. ...
... ... Second Wave of H1N1 Flu: No Waiting in Long Lines , ... San Diego, Calif. (Vocus) January 25, 2009 -- U.S. ... nation, announced today that they are offering H1N1 vaccine shots for $15 per shot for ...
... for surgery than county hospitals, research shows , MONDAY, ... received by prostate cancer patients is influenced by the ... a new U.S. study has found. , Surgery was ... while patients in private facilities were more likely to ...
... , ROCHESTER, Minn. , Jan. ... the brain is the aim of a new Mayo Clinic project ... The new method uses analytics technology developed by the Mayo and ... 95 percent accuracy rate in detecting aneurysms, compared with 70 percent ...
... , NEW YORK , ... of the 25 largest PR firms ( http://www.5wpr.net/ ) in the U.S., today ... its versatile roster of fashion and lifestyle clients. Launched in 2002, the luxury ... lifestyle products using proprietary natural frequency technology. , " Philip Stein is ...
... CHESAPEAKE, Va. , Jan. 25 U.S.-based, Maison ... Haiti -based Maison Fortune Orphanage. The strategic expansion plans ... after the recent devastating earthquakes. The Orphanage, located near the ... in a sea of unimaginable turmoil. , This planned expansion ...
Cached Medicine News:Health News:Control of herpes symptoms does not reduce HIV transmission, international study found 2Health News:U.S. HealthWorks in San Diego Region Offering $15 H1N1 Vaccinations for both Walk-Ins and On-Site 2Health News:Prostate Cancer Care Varies By Hospital Type 2Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 2Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 3Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 4Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 2Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 3Health News:Haitian Orphanage Takes Quick Action to Fill Void after Devastating Earthquakes 2Health News:Haitian Orphanage Takes Quick Action to Fill Void after Devastating Earthquakes 3
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
... a comprehensive, authoritative drug reference to ... overdose management, Canadian drug names, OTC ... drug references and tools is included ... (ED, PRIMARY CARE PLUS, CRC, RN, ...
... patients and health consumers from the trusted ... in MedMaster includes why the medication is ... side effects and warning signs of adverse ... information on what to do if a ...
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Medicine Products: